sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(16)

<< < 1 > >>

Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage
N. Henke, R. Schmidt-Ullrich, R. Dechend, J. K. Park, F. Qadri, M. Wellner, M. Obst, V. Gross, R. Dietz, F. C. Luft, C. Scheidereit, and D. N. Muller Circ.Res. 101(3):268-276 (2007)
to & Adhesion Albuminuria Angiotensin Animals Atherosclerosis B Blood C57BL Cardiovascular Cell Cells Chain Chloride Cultured Dietary Diseases Endothelial Ester Expression Factor-alpha Fusion Gene Humans Hypertension I-kappa II III Inbred Inflammation Intercellular Kidney Methyl Mice Models Molecule-1 NF-kappa NG-Nitroarginine Necrosis Nephritis Nitric Organ Oxide Polymerase Pressure Proteins Reaction Receptor Recombinant Regulation Research Reverse Signal Sodium Specificity Synthase TIE-1 Transcriptase Transduction Transgenic Tumor Type Vascular antagonists biosynthesis blood cells complications control etiology genetics inhibitors metabolism physiology physiopathology prevention protein toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu, M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. van den Abbeele, G. D. Demetri, T. Force, and M. H. Chen Lancet 370(9604):2011-2019 (2007)
to & Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
T. Force, D. S. Krause, and R. A. van Etten Nat.Rev.Cancer 7(5):332-344 (2007)
to & Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Brian I. Rini Clin Cancer Res 13(4):1098-1106 (2007)
to Antibodies Carcinoma Patient Selection Tyrosine therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a review
F. A. Eskens, and J. Verweij Eur.J.Cancer 42(18):3127-3139 (2006)
to & A Angiogenesis Antibodies Endothelial Factor Growth Humans Inhibitors Kinase Kinases Medical Monoclonal Neoplasms Neovascularization Oncology Pathologic Protein Protein-Tyrosine Receptors Tyrosine Vascular adverse antagonists blood control drug effects inhibitors prevention protein supply therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
H. M. Verheul, and H. M. Pinedo Nat.Rev.Cancer 7(6):475-485 (2007)
to & A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?
J. Wood, E. Scott, and A. L. Thomas Expert.Opin.Investig.Drugs 18(11):1701-1714 (2009)
to Growth Tyrosine response toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom J.Clin.Oncol. 27(25):4169-4176 (2009)
to & A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
M. Schmidinger, C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, M. Ruhsam, M. Hejna, and H. Schmidinger J.Clin.Oncol. 26(32):5204-5212 (2008)
to 80 Aged Arteries Artery Benzenesulfonates Biological Carcinoma Cardiovascular Cell Coronary Disease Diseases Echocardiography Electrocardiography Estimate Factors Failure Female Heart Humans Hypertension Indoles Inhibitors Kaplan-Meiers Kidney Kinase Male Markers Metastasis Middle Neoplasm Neoplasms Outcome Prospective Protein Pyridines Pyrroles Renal Research Risk Studies Time Treatment Tyrosine adverse and blood chemically diagnosis drug effects enzymology induced methods mortality over pathology protein therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, M. Dickler, E. A. Perez, M. Cobleigh, T. Shenkier, S. Edgerton, and K. D. Miller J.Clin.Oncol. 26(28):4672-4678 (2008)
to & A Antibodies Antineoplastic Breast Chemotherapy Combined Dna Endothelial Factor Female Genotype Growth Haplotypes Hazards Humans Hypertension Models Monoclonal Neoplasms Nonparametric Nucleotide Paclitaxel Polymorphism Proportional Protocols Rate Receptor-2 Research Retrospective Single Statistics Studies Survival Vascular administration dosage drug genetics methods pathology therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway
J. M. Roodhart, M. H. Langenberg, E. Witteveen, and E. E. Voest Curr.Clin.Pharmacol. 3(2):132-143 (2008)
to & A Agents Angiogenesis Animals Antibodies Antineoplastic Blood Coagulation Diseases Disorders Endothelial Factor Growth Humans Hypertension Hypothyroidism Inhibitors Intestinal Medical Nervous Oncology Perforation Proteinuria Receptors Signal System Transduction Tyrosine Vascular adverse antagonists chemically drug effects induced inhibitors pathology therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
G. Shankar, V. Devanarayan, L. Amaravadi, Y. C. Barrett, R. Bowsher, D. Finco-Kent, M. Fiscella, B. Gorovits, S. Kirschner, M. Moxness, T. Parish, V. Quarmby, H. Smith, W. Smith, L. A. Zuckerman, and E. Koren J.Pharm.Biomed.Anal. 48(5):1267-1281 (2008)
to Antibodies Human Humans Immunoassay Laboratories Proteins Research methods pharmacology protein response toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Soluble receptors in human disease
M. L. Heaney, and D. W. Golde J.Leukoc.Biol. 64(2):135-146 (1998)
to Cytokine Cytokines Diseases Extracellular Growth Hormones Human Humans Immune Ligands Receptors Research Solubility Space System genetics immunology metabolism pathology therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia AML or not amenable to conventional therapy for the disease
W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A. M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, S. G. Louie, W. Hong, N. M. Brega, G. Massimini, P. Scigalla, W. E. Berdel, and D. K. Hossfeld Blood 105(3):986-993 (2005)
to & 3 Acute Aged Clearance Endothelial Factor Female Follow-Up Genotype Growth Human Humans Hypertension Indoles Kinase Kinases Leukemia Lung Male Metabolic Middle Mutation Myeloid Pharmacokinetics Platelet-Derived Protein-Tyrosine Proteins Proto-Oncogene Pyrroles Rate Receptor Receptors Research SU11248 Studies Tyrosine Vascular analysis antagonists cells drug fms-Like genetics inhibitors protein response therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report
J. W. Lee, R. S. Weiner, J. M. Sailstad, R. R. Bowsher, D. W. Knuth, P. J. O'Brien, J. L. Fourcroy, R. Dixit, L. Pandite, R. G. Pietrusko, H. D. Soares, V. Quarmby, O. L. Vesterqvist, D. M. Potter, J. L. Witliff, H. A. Fritche, T. O'Leary, L. Perlee, S. Kadam, and J. A. Wagner Pharm.Res. 22(4):499-511 (2005)
to Assay Biological Chemistry Clinical Markers Pharmaceutical Reproducibility Research Results Topic Trials analysis as methods of standards toxicity trends by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 > >>publications per page: 5 10 20 50 100

a gripper